Pharmarise narrows loss as profit rebounds, keeps full-year outlook and dividend plan

An announcement from Pharmarise Holdings Corp. ( (JP:2796) ) is now available.

Pharmarise Holdings reported consolidated net sales of ¥50.6 billion for the first nine months of the fiscal year ending May 31, 2026, up 8.5% year on year, with operating profit surging to ¥603 million after a sharp improvement from the prior-year period’s weak earnings. Despite the turnaround at the operating level, the company still posted a small loss attributable to owners of the parent, while equity and the equity ratio edged down slightly, indicating gradual balance sheet pressure as it pursues profit recovery.

The company kept its dividend policy intact, paying no interim dividend but maintaining a full-year forecast of ¥14 per share, signaling confidence in cash generation despite the modest net loss year to date. Full-year guidance was left unchanged, with management projecting further growth to ¥66.8 billion in net sales and a strong rebound in profitability, suggesting that Pharmarise expects its operational improvements to solidify and support shareholder returns in the current fiscal year.

The most recent analyst rating on (JP:2796) stock is a Hold with a Yen553.00 price target. To see the full list of analyst forecasts on Pharmarise Holdings Corp. stock, see the JP:2796 Stock Forecast page.

More about Pharmarise Holdings Corp.

Pharmarise Holdings Corporation is a Japan-based company listed on the Tokyo Stock Exchange Standard Market, operating in the pharmacy and pharmaceutical retail sector. The group focuses on dispensing pharmacies and related healthcare services, generating revenue from prescription drug sales and allied medical support in the domestic market.

Average Trading Volume: 9,171

Technical Sentiment Signal: Sell

Current Market Cap: Yen6.07B

Learn more about 2796 stock on TipRanks’ Stock Analysis page.